A study to assess the correlation between plasma, oral fluid and urine concentrations of flunixin meglumine with the tissue residue depletion profile in finishing-age swine
BMC Veterinary Research volume 16, Article number: 211 (2020)
Flunixin meglumine (FM) was investigated for the effectiveness of plasma, oral fluid, and urine concentrations to predict tissue residue depletion profiles in finishing-age swine, along with the potential for untreated pigs to acquire tissue residues following commingled housing with FM-treated pigs. Twenty pigs were housed in groups of three treated and one untreated control. Treated pigs received one 2.2 mg/kg dose of FM intramuscularly. Before treatment and at 1, 3, 6, 12, 24, 36, and 48 h (h) after treatment, plasma samples were taken. At 1, 4, 8, 12 and 16 days (d) post-treatment, necropsy and collection of plasma, urine, oral fluid, muscle, liver, kidney, and injection site samples took place. Analysis of flunixin concentrations using liquid chromatography/tandem mass spectrometry was done. A published physiologically based pharmacokinetic (PBPK) model for flunixin in cattle was extrapolated to swine to simulate the measured data.
Plasma concentrations of flunixin were the highest at 1 h post-treatment, ranging from 1534 to 7040 ng/mL, and were less than limit of quantification (LOQ) of 5 ng/mL in all samples on Day 4. Flunixin was detected in the liver and kidney only on Day 1, but was not found 4–16 d post-treatment. Flunixin was either not seen or found less than LOQ in the muscle, with the exception of one sample on Day 16 at a level close to LOQ. Flunixin was found in the urine of untreated pigs after commingled housing with FM-treated pigs. The PBPK model adequately correlated plasma, oral fluid and urine concentrations of flunixin with residue depletion profiles in liver, kidney, and muscle of finishing-age pigs, especially within 24 h after dosing.
Results indicate untreated pigs can be exposed to flunixin by shared housing with FM-treated pigs due to environmental contamination. Plasma and urine samples may serve as less invasive and more easily accessible biological matrices to predict tissue residue statuses of flunixin in pigs at earlier time points (≤24 h) by using a PBPK model.
Flunixin meglumine (FM) (Banamine-S®, Merck Animal Health, Madison, NJ) is approved as an intramuscular (IM) injection for pyrexia control associated with swine respiratory disease  and is available for intravenous (IV) and oral administration in other livestock species . It is labeled for use in the United States for beef cattle, dairy cattle, horses and swine [2, 3]. It has been utilized with pharmacokinetic parameters assessed in numerous species [4,5,6,7,8,9,10,11,12,13,14,15,16]. Pharmacokinetic properties of FM have been described in smaller non-breeding aged swine with weights ranging from 20 kg to 40 kg [3, 17, 18], mature swine (152–168 kg) , and sows (187–259 kg) , but scant research findings exist on finishing-age swine (90–130 kg).
Finishing-age swine tissues as they relate to the proximity to human consumption set them apart as important with regard to treatment decisions. A safe, healthy product for pork consumers is paramount. FM is regularly utilized as an adjunctive treatment in respiratory disease of finishing swine. Respiratory diseases rank among the most serious disease problems and pose remarkable problems to swine production today . However, these threats also open opportunities for interventions through antimicrobials and adjunctive treatments such as FM.
Details of flunixin drug tissue residues and alternative methods of residue detection in finishing-age swine is limited. The labeled tissue withdrawal period for FM in swine is 12 d . Traditional plasma and carcass sampling provides drug residue measurement in conjunction with emerging means, such as analysis of oral fluids and urine. Oral fluids are already utilized efficiently to detect diseases  and antimicrobial residues  in swine. Coordinating sampling methodology should help develop a less-invasive, more easily administered antemortem monitoring procedure.
Searches for peer-reviewed literature show limited research on carcass residue effects of FM in finishing-age swine and their association with other sampling methods. In the only swine study found, Magyar and Glavits  demonstrated FM had significantly (p < 0.05) worse carcass lesions than meloxicam, grossly visible out to 15 d after administration. In other species, flunixin is the second-most common residue violation in cull dairy cattle . It is labeled for IV injection and requires a withdrawal period of 4 d in cattle (excluding veal calves). Kissell et al.  demonstrated the extended duration of tissue and milk residues when FM was given by IM and SQ in cattle. In addition, environmental contamination with drug residues represents another serious consideration. In a study by Popot et al. , horses given FM while staying in the same stall with no daily bedding change had flunixin levels in urine that were detectably extended. It was concluded this was likely from ingestion of bedding contaminated by urine because renal clearance is the main route of flunixin excretion. These factors need to be kept in mind in pork residues as well.
The objectives of this study were to: 1) determine the potential correlation of plasma, oral fluid, and urine concentrations of flunixin with its residue depletion kinetic profiles in edible tissues of finishing-age pigs, 2) evaluate the potential for flunixin exposure of untreated pigs by treated pigs due to environmental contamination, and 3) evaluate the effectiveness of describing plasma, urine and oral fluid flunixin levels as potential biomarkers of tissue residue statuses in swine. The objectives of this study aim to advance understanding of flunixin tissue residues in swine and provide novel testing methods to limit carcass tissue residues.
The concentrations of flunixin and its metabolite 5-hydroxyflunixin in the plasma of finishing-age swine after IM administration of FM at 2.2 mg/kg are presented in Tables 1 and 2, respectively. Plasma concentration data are reported as a number or <LOQ. Over 90% of the <LOQ for the plasma samples were not detected, but there were seven samples above the LOD of 3 ng/mL and below the LOQ of 5 ng/mL; and four of these seven samples belonged to the control group where all of the other time points were not detected. The other three samples were from animals 269, 258, and 272, and might due to possible contamination at some point in the process. These seven samples prompted us to present <LOQ or a number in Tables 1 and 2.
At pre-treatment of 0 h, the concentrations of both flunixin and 5-hydroxyflunixin in all plasma samples were less than LOQ of 5 ng/mL. Flunixin concentrations were the highest at 1 h post-treatment, with a range of 1534–7040 ng/mL, indicating a high variability in the plasma concentration of flunixin after IM administration. From 1 h to 48 h post-treatment, the concentration of flunixin continued to drop. At 96 h post-treatment, the concentration of flunixin was less than LOQ in all collected plasma samples.
Compared to flunixin, the concentrations of 5-hydroxyflunixin in the plasma had relatively higher variability (Table 2). At 1 h after treatment, three of the fifteen plasma samples from FM-treated swine had 5-hydroxyflunixin concentrations less than LOQ of 5 ng/mL; and the levels ranged from 61 to 321 ng/mL in the remaining twelve samples. Concentrations of 5-hydroxyflunixin in the plasma fell over time. At 48 h post-treatment, the concentration of 5-hydroxyflunixin was less than LOQ in all collected plasma samples.
Tissue residue depletion
Concentrations of flunixin and 5-hydroxyflunixin in the tissues of finishing-age swine after IM administration of FM at 2.2 mg/kg are presented in Tables 3 and 4, respectively. On Day 1 (at 24 h) after treatment, concentrations of flunixin fell in the range of 77.5 to 160.1 ng/g in kidney, from 98.6 to 326.8 ng/g in liver (higher than the tolerance of 30 ng/g in liver), and were either <LOQ or not found in the muscle. From Day 2 to Day 16, all liver, kidney, and muscle samples showed flunixin concentrations less than LOQ, except one muscle sample on Day 16 that was 9.8 ng/g, which is lower than the tolerance of 25 ng/g in muscle of swine. In the injection site on Day 1, flunixin concentrations ranged widely, from 7.5 to 40,143.4 ng/g. Flunixin was still found in one of the three treated injection site samples on Day 12 after treatment, but flunixin was less than LOQ in all samples on Day 16 after dosage. Similar to flunixin, 5-hydroxyflunixin was found on Day 1, but not on Days 2–16 in kidney and liver. In the muscle, 5-hydroxyflunixin did not appear at any sampling period. In the injection site, 5-hydroxyflunixin was either not found or less than LOQ from Day 1 to Day 16 after treatment.
Concentrations in urine and Oral fluids
Flunixin and 5-hydroxyflunixin concentrations in urine and oral fluid samples from finishing-age swine after IM administration of FM at 2.2 mg/kg are reported in Table 5. Flunixin showed in the urine up to Day 4 after treatment, but it was either not found or less than LOQ after 8 d and 16 d. On Day 1, 5-hydroxyflunixin was found in the urine, but it was either less than LOQ or not found from Days 2–16. Concentrations of flunixin and 5-hydroxyflunixin in the pen-level oral fluid samples varied greatly. Flunixin was quantifiable on Days 1, 4, and 12, but not on Days 8 and 16. Meanwhile, 5-hydroxyflunixin was quantifiable on Days 1, 4, 12, and 16 at low levels (10.6–21.0 ng/mL), but not on Day 8.
PBPK model simulation
PBPK model simulations of plasma, tissue, oral fluid, and urine concentrations of flunixin were compared with measured data in pigs exposed to 2.2 mg/kg FM via IM administration (Fig. 1). The model successfully simulated the observed flunixin concentrations in the plasma, especially within 24 h after treatment (Fig. 1a). At later time points (≥48 h), observed data are not shown because the majority of the observed values in plasma were lower than LOQ (Tables 1 and 2). To be more specific, at 48 h, observed flunixin levels were < LOQ in six out of the twelve experimental animals, and at ≥96 h observed values were < LOQ in all animals (Table 1). These experimentally-measured results were also consistent with the PBPK model-simulated values, which were < LOQ (e.g., 1.85 ng/ml at 48 h) at all these later time points.
After calibration with observed plasma concentration data, the PBPK model was directly employed to simulate liver flunixin concentrations and it adequately simulated the concentration at 24 h (Fig. 1b). At ≥96 h, flunixin was not found in the liver. These numbers were consistent with model-predicted results that were either close to or < LOQ in the liver at these studied time points (≥96 h). In the original PBPK model in cattle , the kidney/plasma partition coefficient for flunixin was not optimized due to insufficient data. In the present study, we estimated this parameter by fitting to the observed kidney concentration data at 24 h (Fig. 1c). By using this estimated partition coefficient, the model-simulated concentrations of flunixin in kidney at ≥96 h were all much lower than LOQ, which corresponded to the experimentally-observed data that were all not found. In addition, model-simulated flunixin levels in muscle at all time points were below LOQ, which correlated with the observed data that were either <LOQ or not found except on Day 16 in Animal 259, where the muscle concentration was 9.8 ng/g (Table 3). It is worth mentioning that concentrations of flunixin found in all the tissues beyond Day 12 (the labeled tissue withdrawal period for FM in pigs) were less than the established tolerance levels of flunixin in swine, which are 30 and 25 ng/g in liver and muscle, respectively .
The present study reports original experimental data on the concentrations of flunixin and its metabolite 5-hydroxyflunixin in plasma, liver, kidney, muscle, injection site, urine, and oral fluid of finishing-age swine after IM administration of FM at the label dose of 2.2 mg/kg. The results fill in the data gaps on the plasma pharmacokinetics and tissue residue depletion profile of flunixin and 5-hydroxyflunixin in finishing-age swine after IM administration. Results indicate the current label withdrawal period of 12 d for flunixin meglumine after a single IM administration at 2.2 mg/kg should be sufficient for finishing-age swine, and untreated pigs can be exposed to flunixin by treated pigs due to environmental contamination. By integrating the experimental data with PBPK modeling, another significant finding is that plasma and urine concentrations may be useful markers to predict tissue residue statuses of flunixin after IM administration in swine by using a PBPK model.
Correlation of urine flunixin concentrations with tissue residue depletion profiles
The PBPK model was employed to predict flunixin concentrations in the urine to assess the potential for using the model to predict residue depletion profiles in edible tissues based on less invasive and easily accessible biological matrices. The model-predicted data were compared to the observed data in spot urine samples collected at slaughter time points (Fig. 1d). Notably, the model-predicted urine flunixin concentrations at 24 h and 96 h were both in the range of observed values, although concentrations at 24 h varied greatly. Specifically, the model-predicted value at 24 h was similar to the measured values in two of the three animals, but was lower than that of the third animal by nearly threefold. This is not surprised as spot urine concentrations of a drug depend on multiple factors, including urinary output, voiding interval time, previous voiding time, and postvoid residual urine volume . As a result, the underestimation of the third animal could be the result of smaller urinary output, longer voiding interval time, and/or larger postvoid residual urine volume than two other animals. Nonetheless, adequate predictions of spot urine flunixin concentrations suggest that the PBPK model can potentially be used to perfrom reverse dosimetry analysis, i.e., to predict the tissue residue depletion profiles based on the experimentally-measured spot urine concentration data. Future studies should consider using metabolism cages to collect cumulative urine samples to further refine this PBPK model.
Assessment of flunixin exposure in untreated pigs due to environmental contamination
At Days 1 and 4 after treatment with sterile water vehicle, control pigs had no detectable concentrations of flunixin or 5-hydroxyflunixin in the plasma (Tables 1 and 2) or tissue samples (Tables 3 and 4). However, flunixin was found in their urine samples by liquid chromatography with tandem mass spectrometry (LC-MS/MS) testing at Days 1 and 4 following vehicle treatment (Table 5). The detection of flunixin at higher concentrations in urine and not in plasma was not unexpected based on earlier studies in horses [26, 30]. Low oral bioavailability of FM in swine  could partially explain why environmental exposure to contaminated urine would be insufficient to result in detectable tissue residues, which was confirmed in current study. On all necropsy days after Day 4, none of the vehicle-treated control pigs had quantifiable flunixin or 5-hydroxyflunixin residues in plasma, urine, or tissue samples.
Examine the effectiveness of determining plasma, urine and oral fluid flunixin concentrations as potential markers of tissue residue status in pigs
To assess the effectiveness of oral fluids as a potential biomarker for predicting tissue residues, the PBPK model was extended to predict flunixin concentrations in oral fluid. The results showed that PBPK model-predicted levels were in the range of the observed concentrations across all slaughter time points, with good correspondence at 24 h (Fig. 1e). However, the measured data at 36 h and 48 h was highly variable, and the model simulations were at the lower end of the range (Fig. 1e). These data indicate that oral fluids at 24 h could be a potentially useful biological matrix for estimating plasma and tissue residue levels of flunixin by utilizing this PBPK model. However, further studies with individual animal data on oral fluid samples at 36 and 48 h are needed to optimize the model.
Parent flunixin showed in urine of all pigs on Day 4 and in the pen-level oral fluids through Day 12 (Table 5), but flunixin did not show in pen-level oral fluids samples on Day 8 after treatment. Additionally, 5-hydroxyflunixin was found in all pen-level oral fluids samples through Day 16, except on Day 8. The reason of the absence of parent flunixin and the metabolite 5-hydroxyflunixin concentrations on Day 8 was unknown, but could relate to sample collection methods or the way in which FM-treated and vehicle-treated control pigs interact with the rope at the pen level. Although analysis of oral fluids could be useful in revealing drug exposure, particularly regarding the assessment of drug metabolites, additional studies in individual and group-housed pigs are needed to improve oral fluids collection method for drug analysis.
Adequacy of the current label withdrawal period of 12 days of flunixin meglumine in pigs
Beyond 24 h after drug treatment, flunixin levels in all studied tissue samples were less than the limit of quantitation of the analytical method (LOQ = 5 ng/g), except in the injection site of one pig at 4 d and one pig at 12 d post treatment and in the muscle of one pig at 16 d post treatment (Table 3). It is important to note that flunixin levels in all tissues after Day 12 (the labeled tissue withdrawal period for FM in swine) fell below established tolerance in swine (30 and 25 ng/g in liver and muscle, respectively)  and therefore indicate no significant food safety concerns. Also, 5-hydroxyflunixin was not seen in any of the studied tissues after 24 h (Table 4).
Limitations of this study
The present study has several limitations. The number of animals was only three per sampling time. This is insufficient to characterize animal population variability. For a tissue residue depletion study designed to determine withdrawal period, at least four (evenly mixed as per sex) animals each slaught time (ideally 5 each time point) are recommended, according to the guidelines from U.S. Food and Drug Administration [31, 32]. Also, concentrations of flunixin and 5-hydroxyflunixin in the edible tissues were found only at one sampling time (i.e., Day 1), insufficient to characterize the tissue residue depletion profiles. Additional studies using a larger number of animals and including sampling times from Day 1 to Day 4 are needed to better characterize the depletion profile of flunixin in finishing-age swine. In addition, the PBPK model used in this study was based on a previously published PBPK model developed in cattle using a legacy software program (acslX) that was discontinued. As a quantitative tool, this model is sufficient to demonstrate the correlation of plasma, urine and tissue concentrations of flunixin. However, for future application, readers are advised to use the recently published more comprehensive PBPK model for flunixin in cattle and swine developed in Berkeley Madonna and was translated to a user-friendly, web-based interactive PBPK (iPBPK) interface using R Shiny .
The present study reports original data on the depletion kinetic profiles of flunixin and its metabolite 5-hydroxyflunixin in the plasma, urine, liver, kidney, muscle, injection site, and oral fluid samples in finishing-age pigs after IM administration of FM at 2.2 mg/kg. A PBPK model in pigs was adapted based on the collected data and a previously published model in cattle . The model adequately correlates plasma, oral fluid and urine concentrations of flunixin with the residue depletion profiles in the liver, kidney, and muscle of finishing-age swine, especially within 24 h after dosing. Plasma, urine, and oral fluid flunixin concentrations can be useful biomarkers for predicting tissue residues in pigs at earlier time points (≤24 h) by using a PBPK model, results of this study suggest. Oral fluids and urine together with a PBPK model can be less invasive and more easily administered antemortem biological monitoring tools for assessing tissue exposure to drugs, especially during the first 24 h after drug exposure. However, this would limit the utility of this system in swine production systems where samples are seldom collected before the end of the label tissue withdrawal period. This system may have more applicability to drugs with longer plasma elimination half-lives that could be found beyond 24 h after administration.
All animal procedures described in this manuscript were approved by the Iowa State University Animal Care and Use Committee (IACUC # 3-14-7768-S) before starting this experiment.
Twenty crossbred barrows (mean body weight: 128.2 kg [282.6 lbs]) were purchased from a commercial swine finishing system (Audubon Manning Veterinary Clinic Management Services, Audubon, IA). None of the twenty pigs had records of prior treatment with flunixin meglumine or other nonsteroidal anti-inflammatory drugs (NSAID). Each pig was confirmed healthy by physical examination. Inclusion criteria included good clinical health with no prior administration of flunixin meglumine. Administration of flunixin meglumine prior to this study excluded any pig from enrollment into this study. Each enrolled pig received a numerical ear tag (Allflex Global Ear Tags, Allflex USA, Inc., DFW Airport, TX, USA) in the right ear and was weighed. A 1-in. diameter, circular tattoo was placed in each pig on the left side in the post-auricular area, around 2 in. ventral to the dorsal midline and 2 in. caudal to the ear. This tattoo was applied on the skin above the trapezius muscle using a commercial tattoo applicator (Stone Mfg., Kansas City, MO, USA) with a slap tattoo. The pigs also had a blood draw to obtain serum to check for pre-treatment levels of flunixin and 5-hydroxyflunixin using the LC-MS/MS method described below.
Pigs were housed in Building 29 of Veterinary Medical Research Institute Facilities at the Iowa State University. The pigs were weighed on arrival and blocked by weight prior to random allocation into treatment groups using a random number generator (Microsoft Excel, Redmond, WA) according to anticipated necropsy date. Five housing groups of four pigs each group were determined and placed in separate rooms based on the planned necropsy date and treatment group (Table S1). In this pharmacokinetic study, there were no statistical hypotheses being tested. Therefore, classical statistical methods (e.g., power analysis) used to calculate sample size were not relevant. However, in this study the sample size of n = 4 pigs per group each necropsy date was based on principles outlined in the book of Comparative Pharmacokinetics - Principles, Techniques, and Applications: “A broad examination of the comparative pharmacokinetic literature suggests that the typical size of an intravenous dose pharmacokinetic trial for a drug with normal variability in the population is approximately four to six animals” .
Animal care and housing conditions were in compliance with the guidelines outlined in the Guide for the Care and Use of Agricultural Animals in Agricultural Use and Research and Teaching 3rd Edition . Pigs were hand-fed once per day with an organic corn/soybean meal diet that met the National Research Council (NRC) nutrient requirements for finishing pigs , and were confirmed free of any medications. Pigs had open access to water through a nipple waterer throughout the study.
Animal phase study design and sample collection
The body weight of each pig was measured the day before treatment to determine accurate dosage. One pig of each housing group was designated the negative control using a random number generator (Microsoft Excel, Redmond, WA), while the other three pigs in the housing group were treated with FM. On the first day of the experiment, each animal was restrained with a hog snare and had a blood sample drawn just before treatment, then each treated pig was given 2.2 mg/kg flunixin meglumine (FM, Banamine-S, Merck Animal Health, Lot # 3037102, Expiration Date: 2/2015) and control pigs were given an equivalent volume of sterile water (VetOne Sterile Water, Nova-Tech, Inc., Grand Island, NE, USA, Lot # B131107–2, Expiration Date: 11/2015). This dose was given IM with a 16-gauge, 1-in. needle inside circular tattoo placed on arrival in the post-auricular area. The information on pig weights and specific treatment given is provided in Table S1 (Supplementary Material).
Blood samples of the pigs (8 mL each sample) were collected at 0, 1, 3, 6, 12, 24, 36 and 48 h after treatment with FM or sterile water via the left or right jugular vein using a 25.4 mm 16-gauge hypodermic needle (Air-Tite Products, Virginia Beach, VA, USA) and 12 mL Luer lock syringe (TycoHealth Care, Mansfield, MA, USA). In addition, just before necropsy for each group, the pigs had a final blood draw. During blood sample collection, animals were restrained manually using a pig snare. To collect oral fluid samples, a ½-inch diameter cotton rope was suspended from a hook hanging to the pig’s shoulder height for around 20–30 min of sampling time to allow each pig to chew on the rope, and then the rope was removed. Oral fluids were extracted by placing the wet portion of the rope into a clean plastic bag and squeezing the rope so the fluid accumulates in the bag, with a minimum of 5 mL being considered as acceptable. Fluids were poured into a cryovial and stored at − 80 °C before analysis.
Necropsy and tissue sample collection took place at 1, 4, 8, 12, and 16 d after treatment with FM or sterile water. Just before euthanasia and necropsy, a 8-mL blood sample were collected at times according to the initial treatment time on Day 1. Pigs were euthanized by penetrating captive bolt followed by exsanguination according to American Veterinary Medical Association guidelines . Urine and tissue samples, including the injection site, liver, kidney, semitendinosus/semimembranosus muscle were collected and stored at − 80 °C before analysis.
Sample processing and analysis
The Iowa State University Veterinary Diagnostic Lab and the Iowa State University-Pharmacology Analytical Support Team (ISU-PhAST) analyzed concentrations of flunixin and its metabolite 5-hydroxyflunixin in plasma, urine, oral fluid, and tissue samples (i.e., liver, kidney, muscle, and injection site). All individuals performing laboratory analysis were blinded to treatment groups. Laboratory samples were labeled in a coded manner, making the treatment status of sample unknown to the laboratory. Blood for analysis was collected in a 10-mL heparinized blood collection tube (BD Vacutainer, Franklin Lakes, NJ, USA) and then centrifuged for 10 min at 1500 g. The plasma was collected and immediately frozen and stored at − 80 °C. Plasma samples were analyzed for flunixin and 5-hydroxyflunixin within 60 d after sample collection and within 10 consecutive days once analysis was started. Urine was collected at necropsy with tissue collection. Three mL of urine was aspirated from the urinary bladder using a 3-mL Luer Lock syringe with an attached 22-gauge × 3/4-in. needle. This sample was placed in a non-additive red top tube and stored at − 80 °C before analysis.
Standards were prepared at a final working concentration ranging from 5 to 5000 ng/mL flunixin and 5-hydroxyflunixin. Internal standard (i.e., flunixin D-3) was added to samples and standards. Oral fluid samples were buffered to a pH of 2.9–3.0; and then flunixin and 5-hydroxyflunixin were extracted using methyl tert-butyl ether. Urine samples were prepared by diluting 0.5 mL urine with water, and then a base catalyzed hydrolysis was performed at the room temperature for 15 min. The diluted urine samples were buffered to a pH of 2.9–3.0 and extracted using 10:1 dichloromethane:petroleum ether. For both oral fluid and urine samples, the organic layer was transferred, dried down and reconstituted in 12.5% acetonitrile in water. Plasma samples were diluted with acetonitrile, centrifuged, and then the supernatant was transferred and dried down. Drugs from tissue samples (liver, kidney, muscle, and injection site) were analyzed using an FSIS method (CLG-MRM 1.02)  with a few modifications. In brief, flunixin and 5-hydroxyflunixin were extracted in 80% (v/v) acetonitrile in water and then further purified using Bakerbond (C18). Both plasma and tissue samples were reconstituted in 25% acetonitrile in water. The recovery of the extraction method for flunixin and 5-hydroxyflunixin from tissues and biological fluids were not measured. However, quality control samples were utilized to ensure that extractions were consistent, precise and reproducible. All samples were transferred to an autosampler vial (with glass insert) and centrifuged before analysis with LC-MS/MS.
A TSQ Quantum Discovery Max triple quadrupole mass spectrometer was used to analyze concentrations of flunixin and 5-hydroxyflunixin in oral fluids and urine. The three ions used in positive ion mode were (m/z) 297 → 109/264/279 for flunixin and (m/z) 313 → 109/280/295 for 5-hydroxyflunixin. Concentrations of flunixin and 5-hydroxyflunixin in plasma samples were measured utilizing an ABSciex QTRAP 4500 mass spectrometer. The three ions measured in negative ion mode were (m/z) 295 → 251, 210, and 197 for flunixin and (m/z) 311 → 267, 227, and 247 for 5-hydroxyflunixin. All curves had a coefficient of determination > 0.99. Limit of quantification (LOQ) for this assay was 5 ng/g or ng/mL for both flunixin and 5-hydroxyflunixin in plasma, oral fluid, tissue, and urine samples. Limit of detection was 3 ng/mL in plasma and 1 ng/mL in oral fluids for both chemicals, and was 2 ng/mL for flunixin and 3 ng/mL for 5-hydroxyflunixin in urine. Plasma samples were run for accuracy and interday and intraday precision. Due to lower sample volume, urine/oral fluids/tissues were each analyzed in a single run so accuracy and interday precision was monitored. Data were accepted only if quality control samples for each run were within 20% of expected nominal levels.
A PBPK model for flunixin in finishing-age pigs was developed via extrapolation from a published PBPK model for flunixin in cattle  and was re-calibrated with the newly collected experimental data from the present study. The model consisted of eight compartments (blood, liver, kidneys, muscle, fat, lungs, richly and slowly perfused tissues) for flunixin and a one-compartment sub-model for pooled metabolites (Figure S1, Supplementary Material). IM injection was simulated as a first-order absorption process with a two-compartment model. The distribution in all compartments was assumed to be blood flow-limited (i.e., perfusion-limited model). The elimination pathways included hepatic metabolism, biliary excretion via liver, and urinary excretion by kidney. The model was updated to include the salivary excretion pathway to assess the potential correlation between plasma, oral fluid and urine levels of flunixin and the residue depletion profiles in edible tissues. Oral fluid concentration of flunixin was defined as plasma level multiplied by saliva/plasma partition coefficient , which was calculated using the mean saliva/plasma area under the concentration ratio method. All physiological parameters were updated to be pig-specific [40, 41]. All chemical-specific parameters remained the same except the absorption parameters, which were estimated by fitting with the newly generated pharmacokinetic data for flunixin in finishing-age pigs from the present study using the Nelder-Mead optimization algorithm in acslX (AEgis Technologies, Inc., Huntsville, AL, USA). All pig-model specific parameters are shown in Table S2 (Supplementary Material). Other parameters and detailed description about model calibration and parameterization processes refer to the original publication  and our recent review article on the principles and methodology of PBPK modeling in veterinary medicine .
Availability of data and materials
All raw experimentally measured concentration data of flunixin and its metabolite 5-hydroxyflunixin in plasma, liver, kidney, muscle, injection site, urine, and oral fluid are presented in Tables 1-5. The PBPK model code in the legacy software format of acslX is available upon request from the corresponding author. Readers are referred to obtain a more recent version of the PBPK model in Berkeley Madonna that has been translated to a web-based interactive PBPK (iPBPK) interface as described in Li et al. .
Interactive physiologically based pharmacokinetic
Liquid chromatography with tandem mass spectrometry
Limit of quantification
National research council
Nonsteroidal anti-inflammatory drug
Physiologically based pharmacokinetic
Merck Animal Health Banamine-S Flunixin Meglumine Label (Injectable Solution Veterinary). 2020. Available at: https://www.merck-animal-health-usa.com/pdfs/swine/Banamine-S_product_bulletin_tcm96-161528.pdf (last accessed date: February 06, 2020).
The Veterinarian’s Guide to Residue Avoidance Management (VetGRAM). Food Animal Residue Avoidance Databank (A component of the Food Animal Residue Avoidance & Depletion Program). Available at: http://www.farad.org/vetgram/search.asp. Accessed 6 Feb 2020.
Buur JL, Baynes RE, Smith G, Riviere JE. Pharmacokinetics of flunixin meglumine in swine after intravenous dosing. J Vet Pharmacol Ther. 2006;29(5):437–40.
Hardie EM, Hardee GE, Rawlings CA. Pharmacokinetics of flunixin meglumine in dogs. Am J Vet Res. 1985;46(1):235–7.
Welsh EM, McKellar QA, Nolan AM. The pharmacokinetics of flunixin meglumine in the sheep. J Vet Pharmacol Ther. 1993;16(2):181–8.
Taylor PM, Winnard JG, Jefferies R, Lees P. Flunixin in the cat: a pharmacodynamic, pharmacokinetic and toxicological study. Br Vet J. 1994;150(3):253–62.
Coakley M, Peck KE, Taylor TS, Matthews NS, Mealey KL. Pharmacokinetics of flunixin meglumine in donkeys, mules, and horses. Am J Vet Res. 1999;60(11):1441–4.
Navarre CB, Ravis WR, Nagilla R, Deshmukh D, Simpkins A, Duran SH, Pugh DG. Pharmacokinetics of flunixin meglumine in llamas following a single intravenous dose. J Vet Pharmacol Ther. 2001;24(5):361–4.
Konigsson K, Torneke K, Engeland IV, Odensvik K, Kindahl H. Pharmacokinetics and pharmacodynamic effects of flunixin after intravenous, intramuscular and oral administration to dairy goats. Acta Vet Scand. 2003;44(3–4):153–9.
Musser JM. Pharmacokinetics of flunixin in chickens after oral and intravenous administration. J Vet Pharmacol Ther. 2010;33(3):312–4.
Kissell LW, Smith GW, Leavens TL, Baynes RE, Wu H, Riviere JE. Plasma pharmacokinetics and milk residues of flunixin and 5-hydroxy flunixin following different routes of administration in dairy cattle. J Dairy Sci. 2012;95(12):7151–7.
Kleinhenz MD, Van Engen NK, Gorden PJ, KuKanich B, Rajewski SM, Walsh P, Coetzee JF. The pharmacokinetics of transdermal flunixin meglumine in Holstein calves. J Vet Pharmacol Ther. 2016;39(6):612–5.
Gorden PJ, Kleinhenz MD, Wulf LW, Rajewski SJ, Wang C, Gehring R, Coetzee JF. Comparative plasma and interstitial fluid pharmacokinetics of flunixin meglumine and ceftiofur hydrochloride following individual and co-administration in dairy cows. J Vet Pharmacol Ther. 2018;41(1):76–82.
Kleinhenz MD, Gorden PJ, Smith JS, Schleining JA, Kleinhenz KE, Wulf LL, Sidhu PK, Rea D, Coetzee JF. Pharmacokinetics of multiple doses of transdermal flunixin meglumine in adult Holstein dairy cows. J Vet Pharmacol Ther. 2018;41(3):490–3.
Morris T, Paine SW, Zahra P, Li E, Colgan S, Karamatic S. Plasma and urine pharmacokinetics of intravenously administered flunixin in greyhound dogs. J Vet Pharmacol Ther. 2019;42(5):505–10.
Reppert EJ, Kleinhenz MD, Montgomery SR, Bornheim HN, Magnin G, Sidhu PK, Zhang Y, Joo H, Coetzee JF. Pharmacokinetics and pharmacodynamics of intravenous and transdermal flunixin meglumine in meat goats. J Vet Pharmacol Ther. 2019;42(3):309–17.
Yu ZG, Jiang CM, Guo YG, Hu YY, Chen DJ. Pharmacokinetics of Flunixin Meglumine after intravenous and intramuscular Administration in Pigs. Agric Sci China. 2007;6(11):1396–401.
Howard JT, Baynes RE, Brooks JD, Yeatts JL, Bellis B, Ashwell MS, Routh P, O'Nan AT, Maltecca C. The effect of breed and sex on sulfamethazine, enrofloxacin, fenbendazole and flunixin meglumine pharmacokinetic parameters in swine. J Vet Pharmacol Ther. 2014;37(6):531–41.
Pairis-Garcia MD, Karriker LA, Johnson AK, Kukanich B, Wulf L, Sander S, Millman ST, Stalder KJ, Coetzee JF. Pharmacokinetics of flunixin meglumine in mature swine after intravenous, intramuscular and oral administration. BMC Vet Res. 2013;9:165.
Cramer MC, Pairis-Garcia MD, Bowman AS, Moeller SJ, Zhang Y, Sidhu PK, Magnin G, Coetzee JF. Pharmacokinetics of transdermal flunixin in sows. J Vet Pharmacol Ther. 2019;42(4):492–5.
VanAlstine WG. Respiratory System. In: Zimmerman JJ, Karriker LA, Ramirez A, Schwartz KJ, Stevenson GW, editors. Diseases of Swine. 10th ed. Chichester, West Sussex, U.K.: Wiley-Blackwell; 2012. p. 348–62.
Ramirez A, Wang C, Prickett JR, Pogranichniy R, Yoon KJ, Main R, Johnson JK, Rademacher C, Hoogland M, Hoffmann P, et al. Efficient surveillance of pig populations using oral fluids. Prev Vet Med. 2012;104(3–4):292–300.
Meiszberg A, Karriker L, Zimmerman J, Irwin C, Coetzee J. Detection of ceftiofur and oxytetracycline in oral fluids of swine with a pen-side competitive ELISA test after intramuscular injection. J Vet Pharmacol Ther. 2011;34(5):515–7.
Magyar T, Glavits R. Clinical comparison of tissue tolerance of meloxicam 20 mg injectable and flunixin injectable in pigs. Pig J. 2007;59:112–24.
Kissell LW, Baynes RE, Riviere JE, Smith GW. Occurrence of flunixin residues in bovine milk samples from the USA. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2013;30(9):1513–6.
Popot MA, Garcia P, Bonnaire Y. Doping control in horses: housing conditions and oral recycling of flunixin by ingestion of contaminated straw. J Vet Pharmacol Ther. 2011;34(6):612–4.
Leavens TL, Tell LA, Kissell LW, Smith GW, Smith DJ, Wagner SA, Shelver WL, Wu H, Baynes RE, Riviere JE. Development of a physiologically based pharmacokinetic model for flunixin in cattle (Bos taurus). Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2014;31(9):1506–21.
Part 556 - Tolerances for residues of new animal drugs in food; Subpart B – Specific tolerances for residues of new animal drugs; Section 556.228 Flunixin. Code of Federal Regulations Title 21. Silver Spring, MD: U.S. Food and Drug Administration; 2020. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=556.286 (last accessed date: February 06, 2020).
Gans JH, Mercer PF. Chapter 37: The Kidneys. In: Swenson MJ, editor. Dukes Physiology of Domestic Animals. 9th ed. Ithaca, NY: Cornell University Press; 1977. p. 463–92.
Gu X, Meleka-Boules M, Chen CL, Ceska DM, Tiffany DM. Determination of flunixin in equine urine and serum by capillary electrophoresis. J Chromatogr B Biomed Sci Appl. 1997;692(1):187–98.
General Principles for Evaluating the Human Food Safety of New Animal Drugs Used in Food-Producing Animals - Guidance for Industry. U.S. Food and Drug Administration, Rockville, MD. 2018. Available at: https://www.fda.gov/media/70028/download (Last accessed date: February 11, 2020).
Guidance for Industry - Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs In Food-Producing Animals. Marker Residue Depletion Studies to Establish Product Withdrawal Periods, VICH GL48(R). Rockville, MD: U.S. Food and Drug Administration; 2015. Available at: https://www.fda.gov/media/78351/download (Last accessed date: February 11, 2020).
Li M, Cheng YH, Chittenden JT, Baynes RE, Tell LA, Davis JL, Vickroy TW, Riviere JE, Lin Z. Integration of food animal residue avoidance databank (FARAD) empirical methods for drug withdrawal interval determination with a mechanistic population-based interactive physiologically based pharmacokinetic (iPBPK) modeling platform: example for flunixin meglumine administration. Arch Toxicol. 2019;93(7):1865–80.
Riviere JE. Comparative Pharmacokinetics: Principles, Techniques, and Applications. Second ed. Chichester: John; 2011. p. 1–443.
Guide for the Care and Use of Agricultural Animals Used in Research and Teaching. Third Edition, pages 142–156. Federation of Animal Science Societies (FASS), Champaign, IL. 2010. Available at: https://www.aaalac.org/about/ag_guide_3rd_ed.pdf (last accessed date: February 06, 2020).
Models for Estimating Nutrient Requirements of Pigs. National Research Council (NRC), National Academy of Sciences, Washington, DC. 2012. Available at: http://dels.nas.edu/resources/static-assets/banr/swine-resources/case-studies-pdf.pdf (last accessed date: February 06, 2020).
AVMA Guidelines for the euthanasia of animals: 2013 edition. American Veterinary Medical Association (AVMA), Schaumburg, IL. 2013. Available at: https://www.avma.org/KB/Policies/Documents/euthanasia.pdf (last accessed date: February 06, 2020).
CLG-MRM1.02, Screening and Confirmation of Animal Drug Residues by UHPLC-MS-MS. United States Department of Agriculture (USDA), Food Safety and Inspection Service, Office of Public Health Science. 2013. Available at: https://www.fsis.usda.gov/horses/CLG-MRM1.pdf (last accessed date: February 06, 2020).
Smith JN, Wang J, Lin Y, Timchalk C. Pharmacokinetics of the chlorpyrifos metabolite 3,5,6-trichloro-2-pyridinol (TCPy) in rat saliva. Toxicol Sci. 2010;113(2):315–25.
Buur JL, Baynes RE, Craigmill AL, Riviere JE. Development of a physiologic-based pharmacokinetic model for estimating sulfamethazine concentrations in swine and application to prediction of violative residues in edible tissues. Am J Vet Res. 2005;66(10):1686–93.
Upton RN. Organ weights and blood flows of sheep and pig for physiological pharmacokinetic modelling. J Pharmacol Toxicol Methods. 2008;58(3):198–205.
Lin Z, Gehring R, Mochel JP, Lave T, Riviere JE. Mathematical modeling and simulation in animal health - part II: principles, methods, applications, and value of physiologically based pharmacokinetic modeling in veterinary medicine and food safety assessment. J Vet Pharmacol Ther. 2016;39(5):421–38.
The authors wish to thank the staff and interns of the Swine Medicine Education Center (Summer 2014).
This research was supported by the Iowa Pork Producers, the National Pork Board (NPB #13–210), and the United States Department of Agriculture (USDA) National Institute of Food and Agriculture (NIFA) for the Food Animal Residue Avoidance Databank (FARAD) program (Award #: 2015–41480-23972). The funders did not play a role in the design of the study, the collection, analysis, and interpretation of the data; or in writing the manuscript.
Ethics approval and consent to participate
The animal experiment was approved by the Institutional Animal Care and Use Committee (IACUC) of the Iowa State University (IACUC # 3-14-7768-S). Animal care and housing conditions were in compliance with the recommendations outlined in the Guide for the Care and Use of Agricultural Animals in Agricultural Use and Research and Teaching 3rd Edition.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
on the study animal weights, necropsy group allocations and treatment information; Table S2. on the parameters used in the PBPK model for flunixin in finishing-age pigs; and Figure S1. on the PBPK model schematic.
About this article
Cite this article
Bates, J.L., Karriker, L.A., Rajewski, S.M. et al. A study to assess the correlation between plasma, oral fluid and urine concentrations of flunixin meglumine with the tissue residue depletion profile in finishing-age swine. BMC Vet Res 16, 211 (2020). https://doi.org/10.1186/s12917-020-02429-w
- Flunixin meglumine
- Food safety
- Physiologically based pharmacokinetic (PBPK) model
- Tissue residue